Novartis AG ADR (NVS)vsOption Care Health Inc (OPCH)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
OPCH
Option Care Health Inc
$23.48
-0.63%
HEALTHCARE · Cap: $3.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 896% more annual revenue ($56.69B vs $5.69B). NVS leads profitability with a 22.5% profit margin vs 3.7%. OPCH appears more attractively valued with a PEG of 1.16. OPCH earns a higher WallStSmart Score of 60/100 (C).
NVS
Buy51
out of 100
Grade: C-
OPCH
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Margin of Safety
-0.1%
Fair Value
$34.63
Current Price
$23.48
$11.15 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
1.9% revenue growth
3.7% margin — thin
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : OPCH
The strongest argument for OPCH centers on P/E Ratio, Price/Book. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : OPCH
The primary concerns for OPCH are Revenue Growth, Profit Margin, Debt/Equity. Thin 3.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
OPCH carries more volatility with a beta of 0.61 — expect wider price swings.
OPCH is growing revenue faster at 1.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
OPCH scores higher overall (60/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Option Care Health Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Option Care Health, Inc. offers infusion services at home and at alternative sites in the United States. The company is headquartered in Bannockburn, Illinois.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?